logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

John S Tyhonas

This inventor holds 16 USPTO granted patents, primarily in Kinase Inhibitors. Top assignees: Kinnate Biopharma Inc., Cardurion Pharmaceuticals, LLC, Celyn Therapeutics, Inc. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John S Tyhonas. Retrieved from https://idiyas.com/inventor/john-s-tyhonas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16

% Patents Active = 68.8

Average Co-Inventor Count = 7.3

ph-index = 6

Forward Citations = 88(Granted Patents)


Location History:

  • Chula Vista, CA (US) (2012)
  • San Diego, CA (US) (2002 - 2023)

Company Filing History:

goldMedal7 out of 14 
 
Kinnate Biopharma Inc.
 patents
silverMedal2 out of 11 
 
Cardurion Pharmaceuticals, LLC
 patents
bronzeMedal1 out of 1 
 
Celyn Therapeutics, Inc
 patent
4. 1 out of 4,520 
 
Eli Lilly and Company
 patents
5. 1 out of 140 
 
Ligand Pharmaceuticals, Inc.
 patents
6. 1 out of 1,232 
 
Takeda Pharmaceutical Company Limited
 patents
7. 3 out of 834,659 
Other
 patents

Years Active: 2002-2026

Loading Chart...
Areas of Expertise:
MET Kinase
Raf Kinases
Cyclin-Dependent Kinases
Fibroblast Growth Factor Receptor
Cardiac Diseases
Renin Inhibitors
PPAR Agonists
Peroxisome Proliferator Activated Receptors
RXR Modulators
Oxazolyl-Aryloxyacetic Acid Derivatives
Pharmacologic Profile
16 patents (USPTO):Explore Patents
1. 12595245 - Inhibitors of MET kinase (2026-04-07),
2. 11814384 - Inhibtors of Raf kinases (2023-11-14),
3. 11753395 - Inhibitors of MET kinase (2023-09-12),
4. 11407737 - Inhibitors of RAF kinases (2022-08-09),
5. 11390618 - Inhibitors of cyclin-dependent kinases (2022-07-19),
6. 11345681 - Inhibitors of fibroblast growth factor receptor kinases (2022-05-31),
7. 11197858 - Substituted amines for treating cardiac diseases (2021-12-14),
8. 11098031 - Inhibitors of RAF kinases (2021-08-24),
9. 10894788 - Inhibitors of cyclin-dependent kinases (2021-01-19),
10. 10543212 - Substituted amines for treating cardiac diseases (2020-01-28),
11. 8138168 - Renin inhibitors (2012-03-20),
12. 7176224 - Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists (2007-02-13),
13. 6825222 - Modulators of peroxisome proliferator activated receptors (2004-11-30),
14. 6610696 - Modulators of peroxisome proliferator activated receptors (2003-08-26),
15. 6593493 - RXR modulators with improved pharmacologic profile (2003-07-15),

Title: The Innovative Contributions of John S. Tyhonas

Introduction

John S. Tyhonas is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 15 patents, he has made strides in developing innovative treatments for various diseases.

Latest Patents

Among his latest patents are the "Inhibitors of Raf Kinases," which provide pharmaceutical compositions comprising compounds that inhibit receptor tyrosine kinase effector, RAF. These compounds are designed for the treatment of diseases. Another notable patent is the "Inhibitors of MET Kinase," which includes pharmaceutical compositions that utilize MET receptor tyrosine kinase inhibitory compounds for disease treatment.

Career Highlights

Throughout his career, John has worked with Kinnate Biopharma Inc., where he has played a crucial role in advancing therapeutic solutions. His expertise in kinase inhibitors has positioned him as a key figure in the pharmaceutical industry.

Collaborations

John has collaborated with notable professionals in his field, including Toufike Kanouni and Stephen W. Kaldor. Their combined efforts have contributed to the development of innovative treatments and advancements in pharmaceutical research.

Conclusion

John S. Tyhonas exemplifies the spirit of innovation in the pharmaceutical industry through his extensive patent portfolio and collaborative efforts. His work continues to impact the treatment of diseases, showcasing the importance of inventors in advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…